Diagnosis of irritable bowel syndrome: Role of potential biomarkers

Gastroenterology Research and Practice

Volumn 2015, Issue , 2015, Pages

  Plavšić, Ivana ^a   Hauser, Goran ^a   Tkalčić, Mladenka ^b   Pletikosić, Sanda ^b   Salkić, Nermin ^c  

^a KBC RIJEKA   (Croatia)

^b Filozofskog fakulteta u Rijeci   (Croatia)

^c UNIVERSITY CLINICAL CENTRE TUZLA   (Bosnia and Herzegovina)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CHROMOGRANIN; CYTOKINE; HYDROCORTISONE;

COMPARATIVE STUDY; DISEASE MARKER; ENDOCRINE SYSTEM; ENVIRONMENTAL FACTOR; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; HUMAN; INFLAMMATION; IRRITABLE COLON; MICROFLORA; NEUROENDOCRINE SYSTEM; PATHOGENESIS; REVIEW;

EID: 84932626079     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2015/490183     Document Type: Review

References (68)

1. L. J. Brandt, W. D. Chey, A. E. Foxx-Orenstein et al., "An evidence-based position statement on the management of irritable bowel syndrome" The American Journal of Gastroenterology, vol. 104, supplement 1, pp. S1-S35, 2009
2. National Collaborating Centre for Nursing and Supportive Care, Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care, 2008
3. M. El-Salhy, "Irritable bowel syndrome: diagnosis and pathogenesis" World Journal of Gastroenterology, vol. 18, no. 37, pp. 5151-5163, 2012
4. E. M. M. Quigley and G. Clarke, "A serologic test for irritable bowel syndrome: real meat or bare bones?" Gastroenterology, vol. 137, no. 6, pp. 2168-2170, 2009
5. M. El-Salhy, D. Gundersen, J. G. Hatlebakk, and T. Hausken, "Chromogranin A cell density as a diagnostic marker for lymphocytic colitis" Digestive Diseases and Sciences, vol. 57, no. 12, pp. 3154-3159, 2012
6. Y. A. Saito, G.M. Petersen, G. R. Locke III, and N. J. Talley, "The genetics of irritable bowel syndrome" Clinical Gastroenterology and Hepatology, vol. 3, no. 11, pp. 1057-1065, 2005
7. Z.-F. Zhang, Z.-J. Duan, L.-X. Wang, D. Yang, G. Zhao, and L. Zhang, "The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-Analysis of 25 studies" BMC Gastroenterology, vol. 14, no. 1, article 23, 2014
8. Y. J. Lee and K. S. Park, "Irritable bowel syndrome: emerging paradigm in pathophysiology" World Journal of Gastroenterology, vol. 20, no. 10, pp. 2456-2469, 2014
9. L. Chang, M. Adeyemo, I. Karagiannidis et al., "Serum and colonicmucosal immunemarkers in irritable bowel syndrome" The American Journal of Gastroenterology, vol. 107, no. 2, pp. 262-272, 2012
10. P. Patel, P. Bercik, D. G. Morgan et al., "Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating" Alimentary Pharmacology & Therapeutics, vol. 41, no. 5, pp. 449-458, 2015
11. C. Cremon, L. Gargano, A. M. Morselli-Labate et al., "Mucosal immune activation in irritable bowel syndrome: genderdependence and association with digestive symptoms" American Journal of Gastroenterology, vol. 104, no. 2, pp. 392-400, 2009
12. G. Barbara, V. Stanghellini, R. de Giorgio, and R. Corinaldesi, "Functional gastrointestinal disorders and mast cells: implications for therapy" Neurogastroenterology & Motility, vol. 18, no. 1, pp. 6-17, 2006
13. J. H. Park, P. L. Rhee, H. S. Kim et al., "Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome" Journal of Gastroenterology and Hepatology, vol. 21, no. 1, pp. 71-78, 2006
14. L. Ohman, S. Isaksson, A. Lundgren, M. Simrn, and H. Sjvall, "A controlled study of colonic immune activity and 7+ blood T lymphocytes in patientswith irritable bowel syndrome" Clinical Gastroenterology and Hepatology, vol. 3, no. 10, pp. 980-986, 2005
15. T. G. Dinan, E. M. M. Quigley, S. M. M. Ahmed et al., "Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?" Gastroenterology, vol. 130, no. 2, pp. 304-311, 2006
16. M. Guilarte, J. Santos, I. de Torres et al., "Diarrhoeapredominant IBS patients show mast cell activation and hyperplasia in the jejunum" Gut, vol. 56, no. 2, pp. 203-209, 2007
17. G. T. Stewart, "Post-dysenteric colitis" British Medical Journal, vol. 1, no. 4650, pp. 405-409, 1950
18. J. Schwille-Kiuntke, P. Enck, C. Zendler et al., "Postinfectious irritable bowel syndrome: Follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter" Neurogastroenterology andMotility, vol. 23, no. 11, pp. e479-e488, 2011
19. C. Swan, N. P. Duroudier, E. Campbell et al., "Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNF" Gut, vol. 62, no. 7, pp. 985-994, 2013
20. Y. Ringel and I. M. Carroll, "Alterations in the intestinal microbiota and functional bowel symptoms" Gastrointestinal Endoscopy Clinics of North America, vol. 19, no. 1, pp. 141-150, 2009
21. M. El-Salhy, D. Gundersen, J. G. Hatlebakk, and T. Hausken, "Low-grade inflammation in the rectum of patients with sporadic irritable bowel syndrome" Molecular Medicine Reports, vol. 7, no. 4, pp. 1081-1085, 2013
22. L. H. Wang, X. C. Fang, and G. Z. Pan, "Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis" Gut, vol. 53, no. 8, pp. 1096-1101, 2004
23. M. Thabane, D. T. Kottachchi, and J. K. Marshall, "Systematic review and meta-Analysis: the incidence and prognosis of postinfectious irritable bowel syndrome" Alimentary Pharmacology & Therapeutics, vol. 26, no. 4, pp. 535-544, 2007
24. E. G. Zoetendal, M. Rajili?-Stojanovi?, and W. M. De Vos, "High-Throughput diversity and functionality analysis of the gastrointestinal tract microbiota" Gut, vol. 57, no. 11, pp. 1605-1615, 2008
25. I. M. Carroll, Y.-H. Chang, J. Park, R. B. Sartor, and Y. Ringel, "Luminal and mucosal-Associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome" Gut Pathogens, vol. 2, no. 1, article 19, 2010
26. P. J. Kennedy, J. F. Cryan, T. G. Dinan, and G. Clarke, "Irritable bowel syndrome: a microbiome-gut-brain axis disorder?" World Journal of Gastroenterology, vol. 20, no. 39, pp. 14105-14125, 2014
27. E. Malinen, L. Krogius-Kurikka, A. Lyra et al., "Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome" World Journal of Gastroenterology, vol. 16, no. 36, pp. 4532-4540, 2010
28. G. Clarke, J. F. Cryan, T. G. Dinan, and E. M. Quigley, "Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria" Alimentary Pharmacology andTherapeutics, vol. 35, no. 4, pp. 403-413, 2012
29. A. A. Villarreal, F. J. Aberger, R. Benrud, and J. D. Gundrum, "Use of broad-spectrum antibiotics and the development of irritable bowel syndrome" Wisconsin Medical Journal, vol. 111, no. 1, pp. 17-20, 2012
30. R. Spiller and C. Lam, "An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome" Journal of Neurogastroenterology and Motility, vol. 18, no. 3, pp. 258-268, 2012
31. S. M. Collins and P. Bercik, "Therelationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease" Gastroenterology, vol. 136, no. 6, pp. 2003-2014, 2009
32. J. Fichna and M. A. Storr, "Brain-gut interactions in IBS" Frontiers in Pharmacology, vol. 3, article 127, 2012
33. L. ?Ohman and M. Simr?n, "New insights into the pathogenesis and pathophysiology of irritable bowel syndrome" Digestive and Liver Disease, vol. 39, no. 3, pp. 201-215, 2007
34. W. I. Khan and J. E. Ghia, "Gut hormones: rmerging role in immune activation and inflammation" Clinical and Experimental Immunology, vol. 161, no. 1, pp. 19-27, 2010
35. Y. Cetin, M. Kuhn, H. Kulaksiz et al., "Enterochromaffin cells of the digestive system: cellular source of guanylin, a guanylate cyclase-Activating peptide" Proceedings of theNationalAcademy of Sciences of theUnited States ofAmerica, vol. 91, no. 8, pp.2935-2939, 1994
36. M. El-Salhy, ? A. Danielsson, R. Stenling, and L. Grimelius, "Colonic endocrine cells in inflammatory bowel disease" Journal of Internal Medicine, vol. 242, no. 5, pp. 413-419, 1997
37. M. D. Coates, C. R. Mahoney, D. R. Linden et al., "Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome" Gastroenterology, vol. 126, no. 7, pp. 1657-1664, 2004
38. M. Simr?n, J. Axelsson, R. Gillberg, H. Abrahamsson, J. Svedlund, and E. S. Bj?rnsson, "Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors" The American Journal of Gastroenterology, vol. 97, no. 2, pp. 389-396, 2002
39. L. Ohman, M. Stridsberg, S. Isaksson, P. Jerlstad, and M. Simrn, "Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?"TheAmerican Journal ofGastroenterology, vol. 107, no. 3, pp. 440-447, 2012
40. B. Eriksson and K. Oberg, "Peptide hormones as tumormarkers in neuroendocrine gastrointestinal tumors" Acta Oncologica, vol. 30, no. 4, pp. 477-483, 1991
41. Biomarkers Definitions Working Group, "Biomarkers and surrogate endpoints: preferred definitions and conceptual framework" Clinical Pharmacology & Therapeutics, vol. 69, no. 3, pp. 89-95, 2001
42. T. J. Connor and B. E. Leonard, "Biologicalmarkers of depression" in Antidepressants: Past, Present and Future, S. Preskorn, J. Feighner, C. Stanga, and R. Ross, Eds., vol. 157, pp. 117-148, Springer, Berlin, Germany, 2004
43. G. Clarke, E. M. M. Quigley, J. F. Cryan, and T. G. Dinan, "Irritable bowel syndrome: towards biomarker identification" Trends inMolecularMedicine, vol. 15, no. 10, pp. 478-489, 2009
44. T. Bennike, S. Birkelund, A. Stensballe, and V. Andersen, "Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies" World Journal of Gastroenterology, vol. 20, no. 12, pp. 3231-3244, 2014
45. K. Hod, R. Dickman, A. Sperber et al., "Assessment of highsensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome" Neurogastroenterology and Motility, vol. 23, no. 12, pp. 1105-1110, 2011
46. G. Hauser, M. Tkalcic, S. Pletikosic, N. Grabar, and D. Stimac, "Erythrocyte sedimentation rate-possible role in determining the existence of the low grade inflammation in Irritable Bowel Syndrome patients" Medical Hypotheses, vol. 78, no. 6, pp. 818-820, 2012
47. D. K. Chitkara, M. A. L. van Tilburg, N. Blois-Martin, and W. E. Whitehead, "Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review" American Journal of Gastroenterology, vol. 103, no. 3, pp. 765-774, 2008
48. E. B. Blanchard, J. M. Lackner, J. Jaccard et al., "The role of stress in symptom exacerbation among IBS patients" Journal of Psychosomatic Research, vol. 64, no. 2, pp. 119-128, 2008
49. P. J. Kennedy, J. F. Cryan, E. M. Quigley, T. G. Dinan, and G. Clarke, "A sustained hypothalamic-pituitary-Adrenal axis response to acute psychosocial stress in irritable bowel syndrome" Psychological Medicine, vol. 44, no. 14, pp. 3123-3134, 2014
50. L. Z. FitzGerald, P. Kehoe, and K. Sinha, "Hypothalamicpituitary-Adrenal axis dysregulation in women with irritable bowel syndrome in response to acute physical stress" Western Journal of Nursing Research, vol. 31, no. 7, pp. 818-836, 2009
51. A. J. Lembo, B. Neri, J. Tolley, D. Barken, S. Carroll, andH. Pan, "Use of serumbiomarkers in a diagnostic test for irritable bowel syndrome" Alimentary Pharmacology andTherapeutics, vol. 29, no. 8, pp. 834-842, 2009
52. D. Zhang, P. Shooshtarizadeh, B.-J. Laventie et al., "Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2" PLoS ONE, vol. 4, no. 2, Article ID e4501, 2009
53. R. Sidhu, M. E. McAlindon, J. S. Leeds, J. Skilling, and D. S. Sanders, "The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome" Journal of Gastrointestinal and Liver Diseases, vol. 18, no. 1, pp. 23-26, 2009
54. S. P. Dunlop, D. Jenkins, K. R. Neal, and R. C. Spiller, "Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS" Gastroenterology, vol. 125, no. 6, pp. 1651-1659, 2003
55. R. Sidhu, K. Drew, M. E. McAlindon, A. J. Lobo, and D. S. Sanders, "Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): a shared model for pathogenesis?" Inflammatory Bowel Diseases, vol. 16, no. 3, p. 361, 2010
56. M. El-Salhy, B. Lomholt-Beck, and T. Hausken, "Chromogranin a as a possible tool in the diagnosis of irritable bowel syndrome" Scandinavian Journal of Gastroenterology, vol. 45, no. 12, pp. 1435-1439, 2010
57. M. Camilleri, "Editorial: fecal granins in IBS: cause or indicator of intestinal or colonic irritation?" The American Journal of Gastroenterology, vol. 107, no. 3, pp. 448-450, 2012
58. A. G. Roseth, M. K. Fagerhol, E. Aadland, and H. Schjonsby, "Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study" Scandinavian Journal of Gastroenterology, vol. 27, no. 9, pp. 793-798, 1992
59. A. Dhaliwal, Z. Zeino, C. Tomkins et al., "Utility of faecal calprotectin in inflammatory bowel disease (IBD):what cut-offs should we apply?" Frontline Gastroenterology, vol. 6, no. 1, pp. 14-19, 2014
60. J. Keohane, C. O'Mahony, L. O'Mahony, S. O'Mahony, E. M. Quigley, and F. Shanahan, "Irritable bowel syndrome-Type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?"TheAmerican Journal of Gastroenterology, vol. 105, no. 8, pp. 1788-1795, 2010
61. J. A. Tibble, G. Sigthorsson, R. Foster, I. Forgacs, and I. Bjarnason, "Use of surrogate markers of inflammation and Rome criteria to distinguish organic fromnonorganic intestinal disease" Gastroenterology, vol. 123, no. 2, pp. 450-460, 2002
62. N. Waugh, E. Cummins, P. Royle et al., "Faecal calprotectin testing for differentiating amongst inflammatory and noninflammatory bowel diseases: systematic review and economic evaluation" Health Technology Assessment, vol. 17, no. 55, 2013
63. M.-H. Chang, J.-W. Chou, S.-M. Chen et al., "Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome" Molecular Medicine Reports, vol. 10, no. 1, pp. 522-526, 2014
64. M. Tkalcic, S. Pletikosic, and G. Hausr, "Biological and psychological determinants of health related quality of life in irritable bowel syndrome patients" Journal of Psychosomatic Research, vol. 76, no. 6, p. 516, 2014
65. J. Langhorst, A. Junge, A. Rueffer et al., "Elevated human-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome" The American Journal of Gastroenterology, vol. 104, no. 2, pp. 404-410, 2009
66. Y. Ding, B. Lu, D. Chen, L. Meng, Y. Shen, and S. Chen, "Proteomic analysis of colonicmucosa in a rat model of irritable bowel syndrome" Proteomics, vol. 10, no. 14, pp. 2620-2630, 2010
67. J. Voss, Y. A. Goo, K. Cain et al., "Searching for the noninvasive biomarker holy grail: are urine proteomics the answer?" Biological Research for Nursing, vol. 13, no. 3, pp. 235-242, 2011
68. M. P. Jones, W. D. Chey, S. Singh et al., "A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads" Alimentary Pharmacology and Therapeutics, vol. 39, no. 4, pp. 426-437, 2014